MedTrace Logo

Follow-up of Study AN004T to Assess the Persistence of AllerT Efficacy During the 2nd to 4th Season After Treatment

NCT02143583 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 196

Last updated 2015-06-24

Study results available
· View outcomes & findings →

Summary

Study aiming to evaluate the efficacy of a 2-month pre-seasonal treatment with an AllerT 50 µg or 100 µg maintenance dose administered in previous study AN004T in reducing symptoms of allergic rhinoconjunctivitis during the 2nd following birch pollen season.

Conditions

  • Birch Pollen Allergy

Sponsors & Collaborators

  • Anergis

    lead INDUSTRY

Principal Investigators

  • Framçois SPERTINI, MD · University of Lausanne Hospitals

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • Denmark
  • France
  • Latvia
  • Lithuania
  • Poland
  • Sweden
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02143583 on ClinicalTrials.gov